HUTCHMED (China) Limited - Asset Resilience Ratio

Latest as of December 2025: 73.92%

HUTCHMED (China) Limited (H7T1) has an Asset Resilience Ratio of 73.92% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€1.30 Billion
≈ $1.52 Billion USD Cash + Short-term Investments

Total Assets

€1.75 Billion
≈ $2.05 Billion USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how HUTCHMED (China) Limited's Asset Resilience Ratio has changed over time. Check HUTCHMED (China) Limited (H7T1) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down HUTCHMED (China) Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see H7T1 stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €1.30 Billion 73.92%
Total Liquid Assets €1.30 Billion 73.92%

Asset Resilience Insights

  • Very High Liquidity: HUTCHMED (China) Limited maintains exceptional liquid asset reserves at 73.92% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

HUTCHMED (China) Limited Industry Peers by Asset Resilience Ratio

Compare HUTCHMED (China) Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
Drug Manufacturers - Specialty & Generic 1.37%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
Drug Manufacturers - Specialty & Generic 0.20%
Celltrion Pharm Inc
KQ:068760
Drug Manufacturers - Specialty & Generic 12.49%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
Drug Manufacturers - Specialty & Generic 0.00%
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
Drug Manufacturers - Specialty & Generic 9.11%

Annual Asset Resilience Ratio for HUTCHMED (China) Limited (2016–2025)

The table below shows the annual Asset Resilience Ratio data for HUTCHMED (China) Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 73.92% €1.30 Billion
≈ $1.52 Billion
€1.75 Billion
≈ $2.05 Billion
+20.39pp
2024-12-31 53.54% €682.15 Million
≈ $797.51 Million
€1.27 Billion
≈ $1.49 Billion
+6.44pp
2023-12-31 47.10% €602.75 Million
≈ $704.67 Million
€1.28 Billion
≈ $1.50 Billion
+16.23pp
2022-12-31 30.86% €317.72 Million
≈ $371.45 Million
€1.03 Billion
≈ $1.20 Billion
-15.34pp
2021-12-31 46.20% €634.16 Million
≈ $741.40 Million
€1.37 Billion
≈ $1.60 Billion
+18.64pp
2020-12-31 27.56% €199.55 Million
≈ $233.29 Million
€724.12 Million
≈ $846.57 Million
+6.91pp
2019-12-31 20.64% €96.01 Million
≈ $112.25 Million
€465.12 Million
≈ $543.78 Million
-19.75pp
2018-12-31 40.39% €214.91 Million
≈ $251.26 Million
€532.12 Million
≈ $622.10 Million
-5.27pp
2017-12-31 45.66% €273.03 Million
≈ $319.20 Million
€597.93 Million
≈ $699.05 Million
+38.58pp
2016-12-31 7.09% €24.27 Million
≈ $28.37 Million
€342.44 Million
≈ $400.34 Million
--
pp = percentage points

About HUTCHMED (China) Limited

F:H7T1 Germany Drug Manufacturers - Specialty & Generic
Market Cap
$1.93 Billion
€1.65 Billion EUR
Market Cap Rank
#6360 Global
#959 in Germany
Share Price
€9.60
Change (1 day)
+0.00%
52-Week Range
€8.45 - €15.00
All Time High
€36.80
About

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more